8-KEarnings & ResultsLeadership ChangesRegulation FD+1

CVS HEALTH Corp 8-K Report, Financial Results (Oct 18, 2024)

Filed October 18, 2024For Securities:CVS

Summary

CVS Health Corporation announced a significant leadership transition, appointing J. David Joyner as the new President and Chief Executive Officer, effective October 17, 2024. This appointment follows the departure of Karen S. Lynch from her CEO role and resignation from the Board of Directors on the same day. Roger N. Farah, the current Chairman, will assume the role of Executive Chairman of the Board. Mr. Joyner brings extensive experience within CVS Health, most recently serving as Executive Vice President and President of Pharmacy Services. His background also includes prior roles in sales and account services within CVS Caremark. The company's announcement, filed on October 18, 2024, also includes preliminary third-quarter 2024 results, though details are incorporated by reference to a furnished press release.

Key Highlights

  • 1J. David Joyner appointed President and Chief Executive Officer, effective October 17, 2024.
  • 2Karen S. Lynch has stepped down as President and Chief Executive Officer and resigned from the Board of Directors.
  • 3Roger N. Farah appointed as Executive Chairman of the Board.
  • 4J. David Joyner has a deep background within CVS Health, including his most recent role as EVP and President of Pharmacy Services.
  • 5Ms. Lynch will receive separation benefits contingent on a release of claims and compliance with restrictive covenants.
  • 6Ms. Lynch will provide advisory services to CVS Health for six months post-departure, receiving a monthly fee of $375,000 and continued security services.
  • 7Restrictive covenants for Ms. Lynch have been extended to 30 months from her departure date.

Frequently Asked Questions

This 8-K filing is primarily to announce a significant change in leadership, specifically the appointment of J. David Joyner as the new President and CEO and the departure of Karen S. Lynch from the same role. It also includes information regarding the appointment of Roger N. Farah as Executive Chairman and incorporates preliminary Q3 2024 results.

J. David Joyner has a long tenure with CVS Health, most recently serving as Executive Vice President and President of Pharmacy Services since January 2023. Prior to that, he held roles such as Executive Vice President – Sales and Account Services, CVS Caremark from 2011 to 2019. His extensive experience within the company positions him to lead.

Karen S. Lynch will receive separation benefits under her existing employment agreement, subject to a release of claims and adherence to restrictive covenants. She will also provide advisory services for six months, earning $375,000 per month, and continue to receive company-provided security. Her non-competition and non-solicitation periods have been extended to 30 months.

While the filing details a change in leadership, it doesn't explicitly state a strategic shift. However, Mr. Joyner's long-standing experience within CVS Health, particularly in Pharmacy Services, suggests continuity in operational focus, while his advisory roles in external health tech and pharma may bring fresh perspectives.